<!DOCTYPE html>
<html>
<head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta name="keywords" content="">
    <meta name="description" content="">
    <title>PaperPass 最权威论文抄袭检测系统</title>
    <link href="../css/bootstrap.css" rel="stylesheet" />
    <link href="../css/style.css" rel="stylesheet" />
</head>
<body>
<div>
    <div class="text-center PT30">
        <ul class="pagination"><li><a href="#"><span>首页</span></a></li>
    <li><a href="#"><span>上一页</span></a></li>
    <li><a href="paper_2.html"><span>下一页</span></a></li>
    <li><a href="paper_9.html"><span>尾页</span></a></li></ul>
    <div class="ML15 inline-block v-top MT10">
            页码
            <span class="g-font-color green">1</span>/<span>9</span>
            页
        </div>    </div>
    <div class="paper-txt P30 PB0">
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="1">1</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">摘 要</span>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="2">2</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">目的：</span><a href='../sentence_detail/2.html' target='right' class='g-font-color orange'>回顾性分析替吉奥单药或联合用药在复发性宫颈癌治疗中的疗效及安全性。</a>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="3">3</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">研究方法：</span><a href='../sentence_detail/4.html' target='right' class='g-font-color orange'>本研究选取了中国医科大学附属盛京医院妇科肿瘤病房32例口服替吉奥的复发性宫颈癌患者，</a><a href='../sentence_detail/5.html' target='right' class='g-font-color orange'>使用替吉奥联合铂类方案患者12例，替吉奥单药方案患者20例。</a><a href='../sentence_detail/6.html' target='right' class='g-font-color orange'>替吉奥联合铂类组的给药方案：</a> <span class="g-font-color green">奥先达80-100 mg/ m2 d1或者卡铂（ GFR+25）＋ AUC(</span> <span class="g-font-color green">5～7.5) d1或者顺铂70 mg/ m2 d1-3；</span> <span class="g-font-color green">替吉奥80mg/m2 d1-d14，每3周重复1次；</span><a href='../sentence_detail/10.html' target='right' class='g-font-color red'>替吉奥单药组给药方案：</a> <span class="g-font-color green">替吉奥80mg/m2 d1-d14，每3周重复1次。</span><a href='../sentence_detail/12.html' target='right' class='g-font-color orange'>主要研究终点为全部患者以及各组分别的疾病控制率（CR+PR+SD），无进展生存期（PFS）和总生存期（OS）；</a><a href='../sentence_detail/13.html' target='right' class='g-font-color orange'>次要研究终点为化疗的毒副反应，主要有血液学毒性、消化道毒性、肝肾功能损伤、皮肤毒性、口腔黏膜炎等。</a> <span class="g-font-color green">每2-3程化疗结束后应用实体瘤缓解评价标准来评价临床控制率；</span><a href='../sentence_detail/15.html' target='right' class='g-font-color orange'>化疗毒副反应则应用NCI常见毒性分级标准来评价。</a>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="4">4</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">结果：</span><a href='../sentence_detail/17.html' target='right' class='g-font-color orange'>1.替吉奥联合铂类组与替吉奥单药组的疾病控制率分别为41.6%和40%（ P=0.607），</a> <span class="g-font-color green">两组总的疾病控制率为40.6%；</span><a href='../sentence_detail/19.html' target='right' class='g-font-color red'>中位无进展生存期分别为5.6个月和4.5个月（ P=0.135），</a><a href='../sentence_detail/20.html' target='right' class='g-font-color red'>中位总生存期分别为12.5个月和11.3个月（ P=0.237），</a><a href='../sentence_detail/21.html' target='right' class='g-font-color orange'>两组总体的中位无进展生存期及总生存期为5.5个月和12.5个月。</a> <span class="g-font-color green">2.最常见的3〜4级不良事件为白细胞减少9.4%（联合组16.7%；</span> <span class="g-font-color green">单药组5%）、贫血12，5%（联合组：</span> <span class="g-font-color green">25%;</span> <span class="g-font-color green">单药组：</span> <span class="g-font-color green">5%）、恶心9.375%（联合组：</span> <span class="g-font-color green">16.7%；</span> <span class="g-font-color green">单药组：</span> <span class="g-font-color green">5%）。</span><a href='../sentence_detail/30.html' target='right' class='g-font-color red'>0级所占比例均是单药组比联合组高，III+IV级均是单药组比联合组低，I-IV级合计也是单药组比联合组低。</a><a href='../sentence_detail/31.html' target='right' class='g-font-color orange'>在白细胞、中性粒细胞、血红蛋白、血小板、恶心呕吐、 AST/ ALT、乏力方面有显著统计学差异，</a> <span class="g-font-color green">在色素沉着、腹泻及口腔黏膜炎无明显差异。</span>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="5">5</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">结论：</span> <span class="g-font-color green">1.本研究结果表明替吉奥联合铂类方案的疾病控制率、无进展生存期、总生存期均优于替吉奥单药方案，</span> <span class="g-font-color green">但均无明显统计学差异。</span><a href='../sentence_detail/36.html' target='right' class='g-font-color orange'>2.替吉奥单药组不良反应较联合组明显减轻，且两组间有显著统计学差异。</a><a href='../sentence_detail/37.html' target='right' class='g-font-color orange'>3.本研究提示替吉奥联合铂类与替吉奥单药方案疗效相似，</a> <span class="g-font-color green">但在安全性方面二者有明显差别，由此我们可推断替吉奥为复发性宫颈癌的</span><a href='../sentence_detail/39.html' target='right' class='g-font-color orange'>患者提供了可选择的有效且毒副作用可耐受的辅助化疗方案。</a>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="6">6</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">关键词：</span><a href='../sentence_detail/41.html' target='right' class='g-font-color orange'>替吉奥，复发性宫颈癌，化疗</a>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="7">7</span>
            <p class="MT20 text-idt25" tpl-section="text">
                <a href='../sentence_detail/42.html' target='right' class='g-font-color red'>替吉奥治疗复发性宫颈癌的临床研究</a>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="8">8</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">1 前言</span>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="9">9</span>
            <p class="MT20 text-idt25" tpl-section="text">
                <a href='../sentence_detail/44.html' target='right' class='g-font-color orange'>宫颈癌的发病率极其高，仅次于乳腺癌和结直肠癌，居全球恶性肿瘤第三位，死亡率居第四位[1-2]；</a><a href='../sentence_detail/45.html' target='right' class='g-font-color orange'>其在发展中国家的发病率和死亡率仅次于乳腺癌，均居第二位。</a> <span class="g-font-color green">我国恶性肿瘤流行病学的数据统计结果中发现[3]，每年我国的新发宫颈癌病例大概有10万左右，</span><a href='../sentence_detail/47.html' target='right' class='g-font-color red'>占全球新发病例的28%，死亡病例大概有3万。</a><a href='../sentence_detail/48.html' target='right' class='g-font-color orange'>罹患宫颈癌的病人经过治疗后，复发的几率约为31%的，其中绝大多数复发的病例在癌症确诊后两年内。</a><a href='../sentence_detail/49.html' target='right' class='g-font-color orange'>宫颈癌一旦复发，其治疗十分困难，疗效有限，预后极差，1年生存率只有10%～15%[4]。</a> <span class="g-font-color green">因此，如何改善复发性宫颈癌患者的疗效，延长生存期，提高生存质量一直是我们妇科肿瘤医学工作者关注的重中之重，重中之难。</span><a href='../sentence_detail/51.html' target='right' class='g-font-color orange'>这就要求我们尽快寻找到复发性宫颈癌的最佳治疗方案，制定个体化方案，使患者获得最大的益处。</a><a href='../sentence_detail/52.html' target='right' class='g-font-color orange'>对于复发性宫颈癌，放疗及手术受到一定的局限性，化疗仍然是主要治疗手段。</a>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="10">10</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">2018年NCCN指南指出；</span><a href='../sentence_detail/54.html' target='right' class='g-font-color orange'>一线单药方案包括紫杉醇、顺铂、卡铂；</a><a href='../sentence_detail/55.html' target='right' class='g-font-color orange'>一线联合化疗方案包括顺铂+紫杉醇±贝伐珠单抗、卡铂+紫杉醇±贝伐珠单抗、</a><a href='../sentence_detail/56.html' target='right' class='g-font-color red'>拓扑替康+紫杉醇±贝伐珠单抗等。</a><a href='../sentence_detail/57.html' target='right' class='g-font-color orange'>二线单药化疗方案包括贝伐单抗、多西他赛、吉西他滨、伊立替康，</a><a href='../sentence_detail/58.html' target='right' class='g-font-color red'>长春瑞滨、5- FU、异环磷酰胺、拓扑替康等。</a> <span class="g-font-color green">如果一线方案治疗效果不佳或者治疗一段时间后病情出现复发或转移，或者因为有一线化疗方案禁忌症等，就需要使用其他方案，也就是二线化疗方案。</span><a href='../sentence_detail/60.html' target='right' class='g-font-color red'>目前提出二线化疗方案尚无统一标准。</a><a href='../sentence_detail/61.html' target='right' class='g-font-color orange'>近几年来，分子靶向治疗的研究越来越多，贝伐单抗-抗肿瘤血管生成药物就是其中之一，它的出现使得复发性宫颈癌患者获得明显的疗效，</a> <span class="g-font-color green">生存期得到延长，生存质量得到改善，但费用实在太高，也只有极少数人能够用上，其他二线化疗效果都不是很理想，</span> <span class="g-font-color green">三线化疗更是少之甚少。</span> <span class="g-font-color green">因此去寻找有效且费用低的化疗药物和（或）化疗方案是我们医学工作者目前急迫需要解决的问题，也是我们以后要努力探索的方向。</span>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="11">11</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">5-Fu曾经在宫颈癌的同步放化疗，辅助化疗，以及姑息性化疗得到了大量的应用，后来因为其严重的消化道毒副作用显著受到限制。</span><a href='../sentence_detail/66.html' target='right' class='g-font-color orange'>替吉奥是含有替加氟、一种口服抗癌药物，替加氟是氟尿嘧啶（5-FU）的前药。</a> <span class="g-font-color green">拮抗5-FU的分解代谢，维持药物血清浓度高[5]。</span> <span class="g-font-color green">国内外很多研究已经证明替吉奥在胃，头颈部，结肠直肠癌，非小细胞肺癌，</span><a href='../sentence_detail/69.html' target='right' class='g-font-color orange'>乳腺癌，胰腺癌和胆管癌患者[6]以及宫颈癌中都有效。</a> <span class="g-font-color green">国外在第二阶段研究 S-1治疗晚期（ FIGO IVB期）或复发性宫颈癌时，</span> <span class="g-font-color green"> Katsumata报道了 S-1用于晚期或复发性宫颈癌的反应率是30.6％，</span> <span class="g-font-color green">中位生存率15.4个月[7]。</span> <span class="g-font-color green">尽管这个发现有希望的，但该研究的限制是以前的化疗方案不允许超过一个才符合资格，</span><a href='../sentence_detail/74.html' target='right' class='g-font-color orange'>结果显示只有48.3％的受试者在初次治疗中接受过化疗治疗。</a> <span class="g-font-color green">但我国关于替吉奥在复发性宫颈癌的姑息性化疗中的疗效研究尚无，且至今无临床实验观察对比</span><a href='../sentence_detail/76.html' target='right' class='g-font-color orange'>分析替吉奥单药与替吉奥联合铂类治疗复发性宫颈癌的疗效及安全性。</a>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="12">12</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">2 资料与方法</span>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="13">13</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">本研究对使用替吉奥单药或联合化疗治疗复发性宫颈癌的疗效与安全性进行回顾性比较分析。</span><a href='../sentence_detail/79.html' target='right' class='g-font-color orange'>我们收集了2016年3月至2018年1月在中国医科大学附属盛京医院妇科肿瘤病房使用替吉奥治疗复发性宫颈癌患者的医疗记录，</a> <span class="g-font-color green">共有32名患者符合本研究标准。</span>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="14">14</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">2.1 纳入标准</span>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="15">15</span>
            <p class="MT20 text-idt25" tpl-section="text">
                <a href='../sentence_detail/82.html' target='right' class='g-font-color orange'>所有患者在接受该治疗之前都进行详细告知，并签署知情同意书。</a> <span class="g-font-color green">所有患者均有靶病灶（根据RECIST标准）。</span><a href='../sentence_detail/84.html' target='right' class='g-font-color orange'>患者年龄≥30岁，体力状况 ECOG（美国东部肿瘤协作组）评分≤2，</a><a href='../sentence_detail/85.html' target='right' class='g-font-color orange'>肝肾功能、心功能及骨髓功能必须合格（血红蛋白≥8 g/ dL；</a> <span class="g-font-color green">粒细胞绝对计数≥1，500/ uL，</span> <span class="g-font-color green">血小板计数≥100，000/ uL，</span> <span class="g-font-color green">血肌酐≥1.5 mg/ dL或肌酐清除率≥60 mL/ min，</span> <span class="g-font-color green">直接胆红素≤正常值上限（ ULN），总胆红素≤1.5× ULN， AST和 ALT≤2.5× ULN）。</span> <span class="g-font-color green">此外，所有患者在S- 1之前接受了一次以上的化疗或放疗或手术方案治疗。</span>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="16">16</span>
            <p class="MT20 text-idt25" tpl-section="text">
                 <span class="g-font-color green">2.2 治疗方案</span>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
        
        <div class="paper-section" tpl-section="warp">
            <span class="label-warning" tpl-section="badge" data-id="17">17</span>
            <p class="MT20 text-idt25" tpl-section="text">
                <a href='../sentence_detail/92.html' target='right' class='g-font-color red'>替吉奥联合铂类组：</a> <span class="g-font-color green">替吉奥（厂家：</span><a href='../sentence_detail/94.html' target='right' class='g-font-color red'>山东新时代药业有限公司 批号：</a> <span class="g-font-color green">20mg 国药准字H20080802，20mg*42粒）:</span> <span class="g-font-color green">80-120mg/m2 ，口服，d1-d14；</span>            </p>
            <div class="text-right">
                <button type="button" tpl-section="btn" class="g-btn g-btn-default g-btn-sm MT10">段落修改</button>
            </div>
            <div tpl-section="box"></div>
        </div>
            </div>
    <div class="text-center PB30">
        <ul class="pagination"><li><a href="#"><span>首页</span></a></li>
    <li><a href="#"><span>上一页</span></a></li>
    <li><a href="paper_2.html"><span>下一页</span></a></li>
    <li><a href="paper_9.html"><span>尾页</span></a></li></ul>
    <div class="ML15 inline-block v-top MT10">
            页码
            <span class="g-font-color green">1</span>/<span>9</span>
            页
        </div>    </div>
    <div style="text-align: center;padding-top:30px">
        <a href="http://www.118qikan.com/?f=pp_report" target="_blank"><img src="http://file.paperpass.com/images/fabiao.jpg"/></a></div>
    <div class="paper-footer">
        <p>检测报告由<a href="http://www.paperpass.com/" target="_blank">PaperPass</a>文献相似度检测系统生成</p>
        <p>Copyright © 2007-2018 PaperPass</p>
    </div>
</div>
</body>
<script type="text/html" template="section">
    <div class="text-right">
        <div class="modifyTxt-notice">
            修改完本段落之后，点击“临时保存”，之后可在上方导航“修改文档”页面中查看修改后的内容
        </div>
        <textarea class="form-control resize-none" rows="4" tpl-section="textarea"></textarea>
        <div class="button-wrap MT10">
            <button type="button" class="g-btn g-btn-default g-btn-sm red" tpl-section-cancle="btn">取消保存</button>
            <button type="button" class="g-btn g-btn-default g-btn-sm" tpl-section-save="btn">临时保存</button>
        </div>
    </div>
</script>
<script type="text/javascript" src="../js/jquery.min.js"></script>
<script type="text/javascript" src="../js/Lib.js"></script>
<script type="text/javascript">
    Report.report_id = '5aa8871a30f49xw47';
</script>
<script type="text/javascript">
    (function(System,$){

        var sectionEdit = System.Paper.sectionEdit();
        var sectionSave = System.Paper.sectionSave(null);
        $(function(){
            $(document).on('click','[tpl-section=btn]',function(){
                sectionEdit.call(this);
            });
            $(document).on('click','[tpl-section-save=btn]',function(){
                sectionSave.call(this);

            });
            $(document).on('click','[tpl-section-cancle=btn]',function(){
                var $warp = $(this).closest('[tpl-section="warp"]');
                $warp.find('[tpl-section="box"]').html('');
            });


        });
    })(Report,jQuery);

</script>
</html>